Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
AssigneesBiogen Idec Inc., Genentech, Inc.
InventorsChristine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
Life of this patent
Estimating the term…
Abstract
Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
Claims9
A method of treating chronic lymphocytic leukemia (CLL) in a human patient, comprising administering rituximab to the patient in an amount effective to treat the CLL, wherein the rituximab is administered to the patient at a dosage of 500 mg/m2.
A method of treating chronic lymphocytic leukemia (CLL) in a human patient, comprising administering rituximab to the patient in an amount effective to treat the CLL, wherein the rituximab is administered to the patient at dosages of 500 mg/m2, and further comprising administering a chemotherapeutic regimen to the patient, wherein the chemotherapeutic regimen comprises fludarabine and cyclophosphamide.
Dependencies are inferred from the claim text.